Delix reports positive Phase 1b data for non-hallucinogenic DLX-001 and FDA clearance of at-home Phase 2

Delix Therapeutics (Private) — Delix Therapeutics announced interim Phase 1b efficacy data for DLX-001 (zalsupindole), an orally bioavailable 5-MeO-DMT analog engineered to promote neuroplasticity without hallucinogenic effects.

Patients showed roughly a 12-point MADRS decrease (about 50%) by day 8, sustained through day 36, with mild, non-serious adverse events. The FDA also cleared a Phase 2 trial design allowing at-home self-administration, a notable regulatory step for the non-hallucinogenic approach.

Source: businesswire.com

For the rest of that week's sector news, read our week in review.